Kiniksa Pharmaceuticals International (KNSA) Amortizatization of Intangibles (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Amortizatization of Intangibles came in at -$93000.0 in Q2 2026, down 111.02% YoY from $844000.0 in Q2 2025, and up 92.86% on a QoQ basis from -$1.3 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 9 years of Amortizatization of Intangibles data on file, last reported at -$93000.0 in Q2 2026.
- Quarterly Amortizatization of Intangibles fell 111.02% year-over-year to -$93000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.1 million (down 515.56% YoY) and the FY2025 annual result came in at $916000.0, up 307.71% from the prior year.
- Amortizatization of Intangibles climbed to -$93000.0 in Q2 2026, from -$1.3 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.2 million in Q2 2023 to a low of -$1.4 million in Q3 2023.
- A 5-year average of $12777.8 and a median of $21500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 1615.79% in 2023, down 1310.92% in 2023.
- Tracing KNSA's Amortizatization of Intangibles over 5 years: stood at $203000.0 in 2022, then surged by 45.81% to $296000.0 in 2023, then tumbled by 376.69% to -$819000.0 in 2024, then jumped by 213.55% to $930000.0 in 2025, then tumbled by 110.0% to -$93000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$93000.0 (Q2 2026), -$1.3 million (Q1 2026), and $930000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn | -93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -93,000.00 |
| Jun 30, 2026 | -93,000.00 |
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | 930,000.00 |
| Dec 31, 2025 | 930,000.00 |
| Sep 30, 2025 | -603,000.00 |
| Sep 30, 2025 | -603,000.00 |
| Jun 30, 2025 | 844,000.00 |
| Jun 30, 2025 | 844,000.00 |
| Mar 31, 2025 | -255,000.00 |
| Mar 31, 2025 | -255,000.00 |
| Dec 31, 2024 | -819,000.00 |
| Dec 31, 2024 | -819,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Mar 31, 2024 | -297,000.00 |
| Mar 31, 2024 | -297,000.00 |